Interferon treatment of hepatitis C virus infection: From basic biology to clinical application

Norihiro Furusyo, Murata Masayuki, Jun Hayashi

研究成果: 著書/レポートタイプへの貢献

1 引用 (Scopus)

抄録

Tremendous progress has been made in the field of antiviral treatment for hepatitis C virus (HCV) infection since the identification of the virus in 1989. Although early treatment regimens with interferon (IFN) alone achieved only limited success, the addition of the broad-spectrum antiviral agent ribavirin has greatly improved response. The primary goal of treatment for HCV infection-viral eradication-is best achieved when the viral level is reduced substantially during the early phase of treatment.Viral eradication is expressive of sustained virological response, the benefits of which are multifactorial and include improved hepatic histology: a decreased occurrence of hepatocellular carcinoma or liver failure and a lower probability of liver-related mortality. Treatment of HCV infection with the current "gold standard" of care-pegylated IFN in combination with ribavirin-is associated with an approximately 50% overall rate of viral eradication, a great improvement over previous IFN treatment regimens. However, more effective and better-tolerated treatments are needed for patients with unfavorable treatment profiles, such as genotype 1, a high viral level at baseline, hepatic steatosis, and poor adherence to treatment due to severe side effects.

元の言語英語
ホスト出版物のタイトルHepatitis C Virus Disease: Immunobiology and Clinical Applications
出版者Springer New York
ページ148-167
ページ数20
ISBN(印刷物)9780387713755
DOI
出版物ステータス出版済み - 2008

Fingerprint

Virus Diseases
Hepacivirus
Interferons
Therapeutics
Ribavirin
Antiviral Agents
Liver
Liver Failure
Standard of Care
Hepatocellular Carcinoma
Histology
Genotype
Viruses
Mortality

All Science Journal Classification (ASJC) codes

  • Medicine(all)

これを引用

Furusyo, N., Masayuki, M., & Hayashi, J. (2008). Interferon treatment of hepatitis C virus infection: From basic biology to clinical application. : Hepatitis C Virus Disease: Immunobiology and Clinical Applications (pp. 148-167). Springer New York. https://doi.org/10.1007/978-0-387-71376-2_8

Interferon treatment of hepatitis C virus infection : From basic biology to clinical application. / Furusyo, Norihiro; Masayuki, Murata; Hayashi, Jun.

Hepatitis C Virus Disease: Immunobiology and Clinical Applications. Springer New York, 2008. p. 148-167.

研究成果: 著書/レポートタイプへの貢献

Furusyo, N, Masayuki, M & Hayashi, J 2008, Interferon treatment of hepatitis C virus infection: From basic biology to clinical application. : Hepatitis C Virus Disease: Immunobiology and Clinical Applications. Springer New York, pp. 148-167. https://doi.org/10.1007/978-0-387-71376-2_8
Furusyo N, Masayuki M, Hayashi J. Interferon treatment of hepatitis C virus infection: From basic biology to clinical application. : Hepatitis C Virus Disease: Immunobiology and Clinical Applications. Springer New York. 2008. p. 148-167 https://doi.org/10.1007/978-0-387-71376-2_8
Furusyo, Norihiro ; Masayuki, Murata ; Hayashi, Jun. / Interferon treatment of hepatitis C virus infection : From basic biology to clinical application. Hepatitis C Virus Disease: Immunobiology and Clinical Applications. Springer New York, 2008. pp. 148-167
@inbook{517be5362b42476f8de557f3541b15a7,
title = "Interferon treatment of hepatitis C virus infection: From basic biology to clinical application",
abstract = "Tremendous progress has been made in the field of antiviral treatment for hepatitis C virus (HCV) infection since the identification of the virus in 1989. Although early treatment regimens with interferon (IFN) alone achieved only limited success, the addition of the broad-spectrum antiviral agent ribavirin has greatly improved response. The primary goal of treatment for HCV infection-viral eradication-is best achieved when the viral level is reduced substantially during the early phase of treatment.Viral eradication is expressive of sustained virological response, the benefits of which are multifactorial and include improved hepatic histology: a decreased occurrence of hepatocellular carcinoma or liver failure and a lower probability of liver-related mortality. Treatment of HCV infection with the current {"}gold standard{"} of care-pegylated IFN in combination with ribavirin-is associated with an approximately 50{\%} overall rate of viral eradication, a great improvement over previous IFN treatment regimens. However, more effective and better-tolerated treatments are needed for patients with unfavorable treatment profiles, such as genotype 1, a high viral level at baseline, hepatic steatosis, and poor adherence to treatment due to severe side effects.",
author = "Norihiro Furusyo and Murata Masayuki and Jun Hayashi",
year = "2008",
doi = "10.1007/978-0-387-71376-2_8",
language = "English",
isbn = "9780387713755",
pages = "148--167",
booktitle = "Hepatitis C Virus Disease: Immunobiology and Clinical Applications",
publisher = "Springer New York",
address = "United States",

}

TY - CHAP

T1 - Interferon treatment of hepatitis C virus infection

T2 - From basic biology to clinical application

AU - Furusyo, Norihiro

AU - Masayuki, Murata

AU - Hayashi, Jun

PY - 2008

Y1 - 2008

N2 - Tremendous progress has been made in the field of antiviral treatment for hepatitis C virus (HCV) infection since the identification of the virus in 1989. Although early treatment regimens with interferon (IFN) alone achieved only limited success, the addition of the broad-spectrum antiviral agent ribavirin has greatly improved response. The primary goal of treatment for HCV infection-viral eradication-is best achieved when the viral level is reduced substantially during the early phase of treatment.Viral eradication is expressive of sustained virological response, the benefits of which are multifactorial and include improved hepatic histology: a decreased occurrence of hepatocellular carcinoma or liver failure and a lower probability of liver-related mortality. Treatment of HCV infection with the current "gold standard" of care-pegylated IFN in combination with ribavirin-is associated with an approximately 50% overall rate of viral eradication, a great improvement over previous IFN treatment regimens. However, more effective and better-tolerated treatments are needed for patients with unfavorable treatment profiles, such as genotype 1, a high viral level at baseline, hepatic steatosis, and poor adherence to treatment due to severe side effects.

AB - Tremendous progress has been made in the field of antiviral treatment for hepatitis C virus (HCV) infection since the identification of the virus in 1989. Although early treatment regimens with interferon (IFN) alone achieved only limited success, the addition of the broad-spectrum antiviral agent ribavirin has greatly improved response. The primary goal of treatment for HCV infection-viral eradication-is best achieved when the viral level is reduced substantially during the early phase of treatment.Viral eradication is expressive of sustained virological response, the benefits of which are multifactorial and include improved hepatic histology: a decreased occurrence of hepatocellular carcinoma or liver failure and a lower probability of liver-related mortality. Treatment of HCV infection with the current "gold standard" of care-pegylated IFN in combination with ribavirin-is associated with an approximately 50% overall rate of viral eradication, a great improvement over previous IFN treatment regimens. However, more effective and better-tolerated treatments are needed for patients with unfavorable treatment profiles, such as genotype 1, a high viral level at baseline, hepatic steatosis, and poor adherence to treatment due to severe side effects.

UR - http://www.scopus.com/inward/record.url?scp=77953361347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953361347&partnerID=8YFLogxK

U2 - 10.1007/978-0-387-71376-2_8

DO - 10.1007/978-0-387-71376-2_8

M3 - Chapter

AN - SCOPUS:77953361347

SN - 9780387713755

SP - 148

EP - 167

BT - Hepatitis C Virus Disease: Immunobiology and Clinical Applications

PB - Springer New York

ER -